Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838252 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL7928045 | 0.89 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL2301205 | 0.89 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL16959889 | 0.89 | ALDH1A1 (0.50) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL1482927 | 0.89 | HTT (0.59) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL30221008 | 0.89 | HTT (0.59) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL20414585 | 0.87 | ALDH1A1 (0.49) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL14645833 | 0.87 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL31227243 | 0.87 | ALDH1A1 (0.49) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL16861397 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110387386-B | Cationic photo-curing fluorine-containing oligomer, anti-fingerprint UV (ultraviolet) ink and application of ink in touch screen display | 惠州市华泓新材料股份有限公司 | 2021-10-15 | — | — | CN | claimed |
| WO-2001020995-A9 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | UNIV WASHINGTON (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2001020995-A1 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | WASHINGTON UNIVERSITY (US) | 2001-03-29 | — | — | WO | claimed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1783108-A1 | METHOD FOR PRODUCING HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| CN-1839135-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-27 | — | — | CN | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2001020995-A9 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | UNIV WASHINGTON (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2001020995-A1 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | WASHINGTON UNIVERSITY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | KDM4E 2516/4885ALDH1A1 39/4885HSD17B10 83/4885 |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | KDM4E 3526/4885ALDH1A1 3497/4885HSD17B10 2419/4885 |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | KDM4E 3526/4885ALDH1A1 3497/4885HSD17B10 2419/4885 |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | ADH1A, ADH1C, CYP4A11 | KDM4E 3330/4885ALDH1A1 168/4885HSD17B10 194/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | KDM4E 3526/4885ALDH1A1 3497/4885HSD17B10 2419/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | KDM4E 3526/4885ALDH1A1 3497/4885HSD17B10 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.